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Objective To study genetic variants and their function within genes
coding for complement receptors in pre-eclampsia.
Design A case–control study.
Setting Pre-eclampsia is a common vascular disease of pregnancy. The
clearance of placenta-derived material is one of the functions of the
complement system in pregnancy.
Population We genotyped 500 women with pre-eclamptic pregnancies
and 190 pregnant women without pre-eclampsia, as controls, from the
FINNPEC cohort, and 122 women with pre-eclamptic pregnancies and
1905 controls from the national FINRISK cohort.
Methods The functional consequences of genotypes discovered by
targeted exomic sequencing were explored by analysing the binding of
the main ligand iC3b to mutated CR3 or CR4, which were transiently
expressed on the surface of COS-1 cells.
Main outcome measures Allele frequencies were compared between
pre-eclamptic pregnancies and controls in genetic studies. The
functional consequences of selected variants were measured by binding
assays.
Results The most significantly pre-eclampsia-linked CR3 variant
M441K (P = 4.27E-4, OR = 1.401, 95% CI = 1.167–1.682) displayed a
trend of increased adhesion to iC3b (P = 0.051). The CR4 variant
A251T was found to enhance the adhesion of CR4 to iC3b, whereas
W48R resulted in a decrease of the binding of CR4 to iC3b.
Conclusions Results suggest that changes in complement-facilitated
phagocytosis are associated with pre-eclampsia. Further studies are needed
to ascertain whether aberrant CR3 and CR4 activity leads to altered pro- and
anti-inflammatory cytokine responses in individuals carrying the associated
variants, and the role of these receptors in pre-eclampsia pathogenesis.
Keywords b2-integrins, complement receptors, complement
system, genetic association, pre-eclampsia, pregnancy.
Tweetable abstract Genetic variants of complement receptors CR3 and
CR4 have functional consequences that are associated with pre-eclampsia.
Linked article This article is commented on by RM Burwick,
p. 1292 in this issue. To view this mini commentary visit
https://doi.org/10.1111/1471-0528.16664.
*A list of FINNPEC board members can be found in the Acknowledgements section.
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Introduction
Pre-eclampsia is a common pregnancy-specific vascular dis-
order that affects 3% of pregnancies.1 It accounts for over
50 000 maternal and 900 000 perinatal deaths annually.2,3
The clinical characteristics are diverse, and the course of
the disease is unpredictable.
Epidemiological evidence indicates that pre-eclampsia is
partially inherited.4–9 Among immunological pathways,
abnormalities in the complement system have recently been
found to be one of the contributing mechanisms in pre-
eclampsia.10–12 The complement system discriminates
between self and non-self structures, causes inflammation,
cell death and tissue destruction, and initiates adaptive
immune responses. Inadequate regulation of the comple-
ment system may result in poor placentation and predis-
pose the pregnancy to pre-eclampsia.13,14 Three pathways
of complement activation lead to a common end point: the
activation of C3 and the terminal pathway, and the forma-
tion of the membrane attack complex (MAC). Genetic
polymorphisms within genes coding for components of the
complement system have been linked to pre-eclampsia sus-
ceptibility.15,16 The levels of C3 are increased in inflamma-
tion but decreased or overactivated in immune diseases
such as systemic lupus erythematosus (SLE), which is
known to predispose women to pre-eclampsia.
When complement is activated, the generated opsonins
C3b and C4b bind covalently to the targets. As activation
of C3 is a critical step in complement activation, it must
be controlled carefully. An important outcome of C3 inac-
tivation is the generation of iC3b molecules, because they
are recognized by complement receptors type 3 (CR3,
CD11b/18, Mac-1 or integrin aMb2) and type 4 (CR4,
CD11c/18, p150.95 or integrin aXb2). CR3 and CR4 are
b2-integrins that function as complement receptors and
specifically recognize iC3b.17,18 Microbes and particles
coated with iC3b are efficiently phagocytosed and eradi-
cated by neutrophils and macrophages. In the absence of
alarm signals indicating infection or major tissue injury,
the iC3b-mediated phagocytosis occurs in a relatively silent
fashion as a basic homeostatic clearance process.
As a result of the rapid growth of the placenta and direct
exposure to maternal blood, it releases microparticles into
the maternal circulation. We have hypothesized that in
pre-eclampsia, a major disorder of pregnancy, the clearance
of the placental particles, cells or their remnants could be
abnormal. Therefore, we have studied the genetic associa-
tions of genes coding for receptors of the complement
system with pre-eclampsia in a large patient cohort.
b2-Integrins may play an important role in mediating the
phagocytosis of particles, e.g. from damaged endothelium
or placenta, as well as for their ability to control the
inflammatory balance of the immune response.
Methods
Subjects and sequencing protocol
Briefly, we studied 500 women with pre-eclamptic pregnan-
cies, who were not obese (with a body mass index of
<30 kg/m2), and 190 pregnant women without pre-eclamp-
sia, as controls, from the Finnish Genetics of Pre-eclampsia
Consortium (FINNPEC) cohort.19 Data were combined with
additional patients and controls from the national FINRISK
study cohort to comprise altogether 609 cases and 2092 con-
trols for association analyses (for details, see Table S1).
Patients were not involved in the research effort. A prede-
fined core outcome set was not used in the study design.
In a previously described custom-made targeted exomic
sequencing protocol,20 we combined an improved Illumina
sequencing library for capture and sequencing with Nim-
bleGen Sequence Capture to study variants within exons of
11 genes coding for receptors of the complement system:
ITGAM (coding for subunit of CR3), ITGAX (coding for
subunit of CR4), CD93, C3AR1, ITGB2, C5AR1, C5AR2,
C1qR, CR2, CR1 and CR1L. A detailed description of the
study materials and methods are available elsewhere.20
Functional studies
To study how variants in the CR3 and CR4 receptors
related to pre-eclampsia affect cell adhesion to iC3b, we
transiently transfected COS-1 cells with either the wild-type
b2-integrin (wt-CR3 or wt-CR4) or one of the mutant
variants (M441K-CR3 and T1000N-CR3 or W48R-CR4 and
A251T-CR4). Expression was established by flow cytometry
and adhesion analyses were conducted according to a pre-
viously published protocol (for details, see Appendix S1).21
In silico studies
Loss-of-function vulnerability score per gene and PolyPhen
and Sift functional in silico analyses per variant were con-
ducted online in VARIANT EFFECT PREDICTOR (VEP; https://
www.ensembl.org/Tools/VEP), with the following annota-
tions: LoF score of <0.2, probably damaging; LoF score of
0.2–0.7, possibly damaging; and LoF score of >0.7, benign.
Modelling of CD11b structure
The CR3 structure was modelled on the basis of the previ-
ously solved CR4 structure (PDB: 3K71, chain G22) using the
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PRIME module of SCHR€ODINGER SUITES 2018-4, (Schr€odinger,
LLC, New York, NY, USA) via the MAESTRO interface.23,24 The
generated model of CD11b was checked manually, especially
for non-similar residues in comparison to CR4. The model
was also verified by checking its Ramachandran diagram.
Statistical methods
Genes with variants associated with pre-eclampsia are listed in
Table 1. Data were analysed with PLINKSEQ, PLINK and R.25 The
significance of the allelic associations was analysed by Fisher’s
exact test. Analysis was divided between low-frequency (minor
allele frequency, MAF < 10%) and common (MAF > 10%)
variants. KAVIAR and VEP 37 were used for additional annota-
tions.26,27 In addition to the appropriate statistical probability
test, odds ratios (ORs) with 95% confidence intervals
(95% CIs) were calculated for all variants. The Student’s t-test
was used for statistical analysis of the functional assays, and a
probability value smaller than 0.05 was considered significant.
Results
Two predisposing variants in ITGAM, coding for the a-
chain of the complement receptor type 3 (CR3, CD11b),
rs41321249 (T1000N; P = 0.044) and rs1143680 (M441K;
P = 4.27E-4), were found to be associated with pre-eclamp-
sia susceptibility by unadjusted association analyses. As
shown in Table 1, the more significant of these alleles,
M441K, was found in 15.4% of women with pre-eclampsia,
as opposed to 11.5% of the controls.
For ITGAX coding for the a-chain of the complement recep-
tor type 4 (CR4, CD11c), three predisposing variants,
rs17853815 (E547K; P = 0.032), rs2230424 (W48R; P = 2.76E-
4) and rs2230428 (A251T; P = 3.47E-5), were found to be
associated with pre-eclampsia susceptibility. Of these, A251T
was found in 20.9% of patients versus 15.7% of controls and
W48R was found in 15.3% of patients versus 11.5% of controls.
Another missense functional variant, rs201463658, was
found in CR2 coding for the complement receptor type 2
(CD21) (P = 0.050, possibly predisposing). This causes the
change S381R, which was found to be ‘probably damaging’
by PolyPhen and deleterious by Sift in the in silico func-
tional analyses. All significant results of the association
analyses are listed in Table 1. All associated variants con-
formed to the proportions of Hardy–Weinberg equilibrium
(HWE, P > 0.05). With mid-range LOFTOOL scores of 0.543
and 0.441 in the ‘possibly damaging’ category, the ITGAM
and ITGAX genes were deemed to be somewhat resistant to
the deleterious effects of variants.
The tail of the P-value distribution of benign variants was as
expected, suggesting that the overall study design and quality
control were successful. Half of the associated variants are
located in genes coding the b2-integrins, and the most promis-
ing of these variants were subjected to functional studies.
Functional analyses of b2-integrin missense
variants related to pre-eclampsia
The CR3 and CR4 integrins are both heterodimeric receptors
consisting of a common b-chain (b2- or CD18) pairing with
different a-chains: CD11b for CR3 and CD11c for CR4,
respectively (Figure 1A,B). The primary protein domains of
CR3 and CR4 and the relative locations of the PE-associated
missense variants are shown in schematic pictures in Fig-
ure 1C, D, whereas the locations of the studied mutations in
the structures of CR3 and CR4 are shown in Figure 2A, B.
To analyse the functional effects of the pre-eclampsia-
associated CR3 and CR4 variants, COS-1 cells were









HWE Consequence (distance from
exon, base pairs)
LoFtool*
rs2230428 ITGAX 3.47E-5 1.416 (1.205–1.664) 0.209 0.157 1 Missense variant, A251T 0.441
rs1143680 ITGAM 4.27E-4 1.401 (1.167–1.682) 0.154 0.115 0.645 Missense variant, M441K 0.543
rs2230424 ITGAX 2.76E-4 1.414 (1.177–1.698) 0.153 0.113 0.643 Missense variant, W48R 0.441
rs55865320 ITGB2 0.019 1.256 (1.041–1.516) 0.141 0.116 1 Intronic variant (11) 0.033
rs201176761 ITGAX 0.019 5.634 (1.094–36.328) 0.004 <0.001 1 Intronic variant (13) 0.441
rs61734513 CR1 0.027 2.824 (1.032–7.515) 0.007 0.003 1 Synonymous variant, C1907C na
rs17853815 ITGAX 0.032 4.311 (0.926–21.758) 0.004 <0.001 1 Missense variant, E547K 0.441
rs2230528 ITGB2 0.036 1.192 (1.013–1.403) 0.200 0.170 0.904 Synonymous variant, G273G 0.033
rs41321249 ITGAM 0.044 1.639 (1.024–2.626) 0.022 0.013 0.348 Missense variant, T1000N 0.543
rs41258244 CD46 0.047 1.368 (0.995–1.863) 0.051 0.038 0.083 Intronic variant (41) 0.983
rs201463658 CR2 0.050 4.596 (0.777–31.418) 0.003 <0.001 1 Missense variant, S381R 0.952
LoF, loss-of-function score from VARIANT EFFECT PREDICTOR (VEP, https://www.ensembl.org/Tools/VEP) indicates the per-gene susceptibility to disease
based on the ratio of loss of function to synonymous mutations in ExAC data; MAF, minor allele frequency; RSID, reference single-nucleotide
polymorphism (SNP) cluster ID.
*LoF score of <0.2, probably damaging; LoF score of 0.2–0.7, possibly damaging; LoF score of >0.7, benign.
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transiently transfected with the variant and wild-type
integrins. As analysed by fluorescence-activated cell sort-
ing (FACS), all the CR3 and CR4 variants were found to
be expressed at equal quantities on the surface of COS-1
cells (Figures 3A and 4A). According to this result, none
of these pre-eclampsia-related CR3 and CR4 missense
variants altered the integrin epitopes in such a way that
would prevent the binding of the b2-integrin antibodies
used in our FACS analysis. Subsequently, COS-1-transfec-
tants were allowed to adhere to the iC3b ligand coated
on plastic. Cell binding of the mutant variants and wild-
type CR3 or CR4 to iC3b is shown in Figures 2B and
3B. The change of methionine 441 to lysine in CD11b
resulted in a trend of increased cell adhesion of unstimu-
lated and PDBu-stimulated M441K-CR3 transfected COS-
1 cells to iC3b. A similar trend was observed in the
iC3b adhesion of threonine to asparagine mutation at
position 1000 (T1000N) in the Calf-2 domain of CR3
(Figure 3B).
The mutation of tryptophan 48 to arginine in CR4
(W48R) decreased the binding of either untreated or PDBu-
activated CR4-transfected COS-1 cells to iC3b (Figure 4B).
In contrast, the mutation of alanine 251 to threonine
(A251T) in the CD11c chain increased the binding of PDBu-
activated COS-1 cells to iC3b compared with wt-CD11c (Fig-
ure 4B). For unstimulated cells, the difference in binding
between the mutant and wild-type CR4 was not significant.
Discussion
Main findings: amino acid variations in CR3 and
CR4 affect iC3b binding
We have discovered that two missense variants in ITGAM
coding for CR3 and three missense variants in ITGAX
Figure 1. The relative locations of the pre-eclampsia-associated missense variants in CR3 or CR4. The complement receptors CR3 and CR4 are
heterodimeric integrin-type receptors comprising a-chains, CD11b for CR3 or CD11c for CR4, that are associated non-covalently with a common b-
chain, CD18. CR3 (A) and CR4 (B) are shown in their inactive and bent forms. The schematic pictures of the primary protein domains in the a-chains
of the b2-integrins show the locations of CR3-related mutations (M441K, T1000N) (C) and the CR4-related mutations (W48R, A251T, E547K) (D).
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coding for CR4 predispose pregnant women to pre-eclamp-
sia. The two variants with strongest association with pre-
eclampsia in each gene were found to have varying func-
tional effects on the respective protein.
The M441K variant in the fourth blade of the b-pro-
peller domain seems to lead to a more adhering form of
the integrin to iC3b, although this result was not statisti-
cally significant and thus warrants further investigation.
M441K is a common variant, with a minor allele frequency
(MAF) of approximately 15%, that strongly predisposes
pregnant women to pre-eclampsia. Another CR3 variant,
M441T (rs1143680), was shown not to affect phagocytosis
of iC3b-coated sheep RBC by CR3-expressing COS-7
cells28. This may reflect the requirement for a positively
charged amino acid at this position for the increased adhe-
sion to iC3b.
In accordance with M441K-CR3, the variant A251T located
in the iC3b-binding I-domain of CR4 was found to increase
adhesion to iC3b (Figure 4B).18 251T, a common variant
(MAF = 20%), is associated with pre-eclampsia with the most
robust probability value among the associations discovered in
complement receptor genes. The stronger adhesion of 251T-
CR4 to iC3b, like 441K-CR3, may result in a shift to a more
inflammatory CR4-mediated response.
In contrast to the above-mentioned variants, the variant
W48R of CR4, located in the first blade of the b-propeller
domain, resulted in a decrease in its binding capacity to
iC3b. As the binding site for iC3b in CR4 appears to be in
the I-domain, and no binding sites in the beta-propeller
have been described,18 the W48R effect on adhesion to
iC3b is probably indirect and may affect the binding of
several ligands. Similar diminished adhesion to iC3b as
observed with W48R on CR4 has previously been shown
with the R77H-substituted CR3, which is associated with
SLE.29 The R77H mutation is located in the second blade
of the b-propeller domain of CR3. In a pregnant woman,
SLE is known to increase the risk of pre-eclampsia between
two- and four-fold.30
Variants were observed as heterozygous mutations with
the exception of one individual, who was found to be
homozygous for the 1000N variant in ITGAM coding for
CR3. She was diagnosed with severe late-onset pre-eclamp-
sia complicated by HELLP syndrome (haemolysis, elevated
liver enzymes and low platelet count) postpartum.
We found that the T1000N predisposing variant of CR3
adhered to iC3b similarly as the wild-type CR3 integrin or
may possibly have an increasing effect. The implications of
T1000N are discussed in Appendix S2.15,18,31-34
Strengths and limitations
The FINNPEC cohort is exhaustively characterized and
allows for specific clinical phenotyping with severe disease,
which is a strength in our study. None of the observed
variants were unique to the patients and they are therefore
unlikely to be the only causative factor of pre-eclampsia in
our cohort. Although iC3b is the main ligand for b2-inte-
grins, the interactions with other ligands were not studied.
Interpretations
The important phagocytic complement receptors CR3 and
CR4 belong to the family of b2-integrins, surface receptors
of leukocytes that play critical roles in innate and adaptive
immune responses. Human CR3 and CR4 share significant
similarity: they are 87% homologous according to the
Figure 2. Locations of the pre-eclampsia-associated missense variants
shown in three-dimensional structural models of CR3 and CR4.
Structural models of CD11b (A) and CD11c (B) indicate the locations of
pre-eclampsia-related variants (based on the crystal structure of CR422).
CR4 is presented from three angles to illustrate the locations of W48R
and E547K variants on opposite sides of the b-propeller domain. Small
arrows point to the positions of the mutations.
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sequence analysis of their encoding cDNAs.35,36 However,
they bind to distinct sites on iC3b.18 CR3 and CR4 are pre-
dominantly expressed on myeloid cells, including neu-
trophilic granulocytes, monocytes, macrophages and
dendritic cells, but are also found on B- and T-lymphocytes
and lymphoid natural killer (NK) cells.37 Although both
integrins are expressed by similar cell types, their patterns
and functions can differ.38–40 CR3 and CR4 have been
reported to bind to many of the same ligands, including
iC3b, ICAM-1 and fibrinogen.37,41
We propose that the genetic variants in CR3 and CR4 may
affect the ability of the maternal system to respond to placental
or endothelial injury or could influence other interactions that
these receptors may have during pregnancy. For example,
changes in the ability to clear placental debris from the mater-
nal circulation may alter waste removal and consequent
inflammatory or coagulation system homeostasis during preg-
nancy. A key causative mechanism of early-onset pre-eclampsia
is suggested to be the shedding of fragmented syncytiotro-
phoblast particles from the placenta into the maternal circula-
tion.42 Accumulating material in blood vessels and kidney
capillaries could thus increase vascular resistance and lead to
increased blood pressure and kidney dysfunction, with conse-
quent proteinuria.43,44 A correlation of complement activation
and antiangiogenic activity has been established, although it
remains unclear whether complement activation is the cause or
the consequence of the antiangiogenic balance observed in pre-
eclampsia.45
The phagocytosis of placental material is assisted by blood
opsonins, such as the complement component iC3b, which is
recognized by the CR3 and CR4 receptors on phagocytic
cells.46,47,48 Opsonization helps the body to maintain home-
ostasis and avoid further tissue damage. Apoptotic cells opso-
nized by iC3b can be ingested by macrophages and dendritic
cells through CR3 and CR4, without triggering inflammatory
responses such as the release of oxygen radicals or pro-
Figure 3. The CR3 mutant M441K, located in the b-propeller domain, adhered more strongly to iC3b than the wild-type CR3 integrin, whereas no
difference in binding between the CR3 mutant T1000N and the wild type was observed. The latter residue is located in the membrane proximal area.
(A) Representative flow cytometry histograms show the equal expression of CD11b and CD18 between the wild-type (wt) and mutant CR3-
transfected COS-1 cells. Shaded areas, non-transfected cells; solid lines, transfected cells. (B) Non-treated or PDBu-activated COS-1 cells transfected
with wt-CD11b/CD18 or M441K-CD11b/CD18 or T1000N-CD11b/CD18 were allowed to bind to iC3b coated on plastic, and bound cells were
detected enzymatically. Cell binding is reported relative to wt-CD11b/CD18 transfectant binding, with wt values defined as 1. Data are from three or
four independent experiments. Error bars represent SDs and horizontal lines show the mean values. *P < 0.05.
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inflammatory cytokines.49–52 b2-Integrins also mediate interac-
tions between immune cells, including the formation of the
immunological synapse between the T-cell and the antigen-
presenting cell. b2-Integrins also influence pro- and anti-in-
flammatory signalling pathways of leukocytes and affect cyto-
kine production.40 b2-Integrins promote leukocyte
extravasation by facilitating interactions between the leukocytes
and endothelium. Leukocyte–endothelial interaction is
increased in pre-eclampsia.53
The engagement of CR3 by iC3b on macrophages may
result in immune-inhibitory responses, such as the produc-
tion of anti-inflammatory cytokines IL-10 and TGF-b that
may block the function of NF-jB, the transcription factor
needed for the promotion of the transcription of many
pro-inflammatory genes.54 Increased serum levels of IL-10
have been reported in the third trimester of pre-eclamptic
pregnancies.55 However, CR3 can also have strong inflam-
matory effects in cell neutrophils and monocytes.40,56,57,58
Women with small-for-gestational-age neonates have a
significantly higher expression of CR3 in their peripheral
blood granulocytes and monocytes than is normal for preg-
nant women. Interestingly, slightly elevated expression
levels of CR3 have been observed in granulocytes in women
with pre-eclampsia.59 Furthermore, a significantly higher
median mean channel brightness (MCB) of CR3 and lower
MCB of CD62L in granulocytes, and high MCB of CR3 in
monocytes, in association with oxidative burst and basal
intracellular reactive oxygen species (iROS) concentration,
have been observed in women with pre-eclampsia.60 In
contrast, CR4-expressing monocytes have been observed in
normal quantities in the peripheral blood of women with
pre-eclampsia.61 CR4 contributes to pro-inflammatory
functions of monocytes, macrophages and dendritic cells.
Conclusion
It is likely that pre-eclampsia develops as a result of multi-
ple genetic and/or environmental factors. Our results reflect
the complex roles of CR3 and CR4 in downstream sig-
nalling and leukocyte function, because b-integrins are
Figure 4. W48R mutation in the b-propeller area decreases and A251T mutation in the I domain increases the adhesion of CR4-integrin to
complement component iC3b. (A) Representative histograms of flow cytometry analysis show an equal expression of CD11c/CD18 between the wild-
type (wt) and mutant CR4-transfected COS-1 cells. Shaded areas, non-transfected cells; solid lines, transfected cells. (B) Non-treated or PDBu-
activated COS-1 cells transfected with wt-CD11c/CD18, W48R-CD11c/CD18 or A251T-CD11c/CD18 were allowed to bind to iC3b coated on plastic,
and bound cells were detected enzymatically. Cell binding is reported relative to wt-CD11c/CD18 transfectant binding, with wt values defined as 1.
Data are from three or four independent experiments. Error bars represent SDs and horizontal lines show the mean values. *P < 0.05.
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clearly involved in both pro-inflammatory and anti-inflam-
matory effects. Future research will decipher whether distur-
bances in the functions of integrins, such as those reported
here, contribute to a shift towards a more pro-inflammatory
immune response, and whether the phenomenon is observed
in non-severe as well as severe pre-eclampsia. On the other
hand, in discordant cases a disruption in the function of
these key receptors may result in the dysregulation of
inflammation in early pregnancy or, perhaps more impor-
tantly, the clearance of placental particles or trophoblast cells
during late pregnancy.
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